When it comes to football, there isn’t much Kendall Simmons hasn’t seen. Throughout his 45 years, MTSU’s second year ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed yesterday at ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK875.00. The company’s shares closed ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Super Bowl 59 is officially in the books with the Philadelphia Eagles beating the Kansas City Chiefs. Here's a look at the ...

Bagmatic NOVO is our new blood collection monitor serving the special needs of mobile blood donations. As a light weight device with outstanding long battery life, it is developed to take a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get into all the earnings and political news ...

For you Super Bowl logo conspiracy theorists out there, this one is going to be tough to crack because there are so many ...

The Super Bowl LX logo has a lot more than two primary colors, prompting many online to theorize several possible matchup combinations.

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Novo Nordisk remains confident in CagriSema’s potential despite underwhelming Phase III results so far. Image credit: Shutterstock/ Kittyfly. Novo Nordisk is planning a new Phase III trial for ...